BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CERN//INDICO//EN
BEGIN:VEVENT
SUMMARY:Impact of PRRT with the use of 90Y/177LuDOTA-TATE to change of SUV
 s obtained in 68Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors
  – does the use of a theroanostic pair of radiopharmaceuticals may affec
 t the estimation of survival after PRRT?
DTSTART;VALUE=DATE-TIME:20211010T141000Z
DTEND;VALUE=DATE-TIME:20211010T143000Z
DTSTAMP;VALUE=DATE-TIME:20260904T164729Z
UID:indico-contribution-271@indico.koza.if.uj.edu.pl
DESCRIPTION:Speakers: Marta Opalińska (University Hospital in Krakow)\nIm
 pact of PRRT with the use of 90Y/177LuDOTA-TATE to change of SUVs obtained
  in 68Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors – does 
 the use of a theroanostic pair of radiopharmaceuticals may affect the esti
 mation of survival after PRRT? \n\nIntroduction\nPeptide receptor radionuc
 lide therapy (PRRT) is an effective therapeutic option for metastatic neur
 oendocrine tumor (NET) therapy in case of good somatostatin receptor expre
 ssion in tumors tissue. Despite significant progress in management of NETs
 \, searching for novel predictive and prognostic factors is crucial. The h
 igh heterogeneity of the somatostatin receptors density in different NET m
 etastatic lesions and inside single tumours probably influence an clinical
  outcome. Some up-to-date studies indicate that the response to PRRT asses
 sed on the basis of imaging of somatostatin receptors may be a potentially
  useful tool for prediction of overall PRRT effect. \n\nAim\nAssessment of
  corrected SUV max change in metastatic NET lesions associated with PRRT c
 ounted in [68Ga]Ga-DOTA-TATE PET/CT and its potential impact on long-term 
 treatment outcomes. \n\nMaterials and Methods\nAmong all patients treated 
 with PRRT using 177Lu or 177Lu/90YDOTA-TATE in 2017-2019 due to disseminat
 ion of G1 and G2 classifications neuroendocrine neoplasm\, 13 patients who
  had 68Ga-DOTATATE PET/CT performed no longer than 6 months before and 6 m
 onths after PRRT. For all measurable metastatic lesions corrected SUVmax (
 taking into account individual for each patients SUV max of reference orga
 ns normal liver or spleen)\, mean value of SUV max in both PET/CTs (before
  and after PRRT) was calculated. Those results were correlated with clinic
 al outcome of the disease assessed during follow-up one on the basis of ot
 her imaging studies as positive (stabilization (SD) or regression (PR)) or
  negative (progression (PD).\n \nResults\nThe mean follow-up was 8.9months
 . PD was found in  patients\, PR or SD in 10 patients. Among patients with
  regression\, a decrease in the mean value of corrected SUVmax in comparis
 on to the baseline study of 277.12% was observed. Among patients with SD\,
  a mean of corrected SUVmax in comparison to the baseline study decreased 
 by 180.80%. Decrease in the mean value of corrected SUVmax in comparison t
 o the baseline study in patients with regression and stabilization taken t
 ogether was in average 209.85% Increased values were observed among progre
 ssive patients\, where change of corrected SUVmax was in average 6.11%. \n
 \nConclusion\nA decrease in the value of corrected SUVmax in metastatic le
 sions obtained from routine PET/CT tests with 68Ga-DOTA-TATE may indicate 
 a lower risk of neuroendocrine tumor progression within a 9 months from th
 e end of PRRT and may constitute an additional independent parameter helpi
 ng to estimate the risk of progression in this group of patients.\n\nhttps
 ://indico.koza.if.uj.edu.pl/event/4/contributions/271/
LOCATION:Theranostics Center / on-line
URL:https://indico.koza.if.uj.edu.pl/event/4/contributions/271/
END:VEVENT
END:VCALENDAR